Apogee Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
APGE Nasdaq 2836 www.apogeetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apogee Therapeutics, Inc.

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results - Nov 10th, 2025 5:10 am
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody - Nov 10th, 2025 5:00 am
Apogee Therapeutics to Participate in Upcoming Conferences - Nov 3rd, 2025 5:30 am
Why Apogee Therapeutics (APGE) Is Up 6.1% After $300 Million Raise to Advance APG777 - Oct 31st, 2025 5:10 pm
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 69.3%: Here's is How to Trade - Oct 30th, 2025 7:55 am
BTIG Maintains a Buy on Apogee Therapeutics (APGE) - Oct 17th, 2025 7:55 pm
Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? - Oct 14th, 2025 7:55 am
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million - Oct 10th, 2025 2:01 pm
Does Apogee Therapeutics' (APGE) $300 Million Raise Mark a Shift in Its R&D Ambition? - Oct 10th, 2025 8:10 am
Apogee Therapeutics (APGE): Assessing Valuation Following $300 Million Equity Raise - Oct 10th, 2025 7:12 am
Why Apogee Therapeutics Stock Triumphed on Thursday - Oct 9th, 2025 3:26 pm
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out - Oct 9th, 2025 2:03 pm
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering - Oct 8th, 2025 7:52 pm
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering - Oct 8th, 2025 2:01 pm
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) With an Outperform Rating - Sep 30th, 2025 2:00 am
Apogee Therapeutics Shares Poised for Upside as Pipeline Targets Multiple Immunology Indications, RBC Says - Sep 25th, 2025 9:01 am
BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis - Sep 15th, 2025 7:09 am
Apogee Therapeutics (APGE) To Showcase APG777 At EADV Congress 2025 - Sep 12th, 2025 12:37 pm
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress - Sep 11th, 2025 5:30 am
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum - Sep 3rd, 2025 5:30 am